Keytruda Injection

Keytruda Injection contains Pembrolizumab, a monoclonal antibody that targets the programmed death receptor-1 (PD-1) on T-cells. It aids in regaining the immune system's capacity to identify and combat cancer cells by inhibiting PD-1.

Brand Name: Keytruda

Composition: Pembrolizumab

Mechanism of Action:

In order to suppress the immune response, pembrolizumab inhibits the PD-1 (programmed death-1) receptor, which often connects with PD-L1 and PD-L2 on tumor cells. Pembrolizumab reactivates T-cells by blocking PD-1, which makes it possible for them to recognize and combat cancer cells.

Uses:

• Non-Small Cell Lung Cancer
• Melanoma
• Head and Neck Squamous Cell Carcinoma
• Classical Hodgkin Lymphoma
• Urothelial Carcinoma
• Renal Cell Carcinoma
• Triple-Negative Breast Cancer
• Esophageal or Gastric Cancers

Dosage and Administration:

Obtainable as a solution or lyophilized powder. Intravenous infusion over a 30-minute period is the administration route.

Side Effects:

·         Hot flashes

·         Sweating

·         Decreased libido

·         Nausea

·         Vomiting

·         Mood changes

·         Bone pain

·         Weight gain

Safety Advise:

Kidney  

Please see your doctor before using Keytruda Injection if you have kidney condition. Before writing a prescription for you, your doctor will consider the advantages and any possible hazards.

Liver  

Please see your doctor before using Keytruda Injection if you have hepatic condition. Before writing a prescription for you, your doctor will consider the advantages and any possible hazards.

Pregnancy  

ecause of the possible risk to the fetus, it is contraindicated. Kindly speak with your Healthcare Professional.

Breast Feeding  

Not recommended for use in breastfeeding women. Kindly speak with your Healthcare Professional.

  Alcohol  

Drinking alcohol while taking Keytruda Injection is not advised. Kindly speak with your Healthcare Professional.

Storage:

Store at 2–8°C  in the original carton to protect from light.Do not freeze or shake

How to use this Medication?

A doctor or nurse at a hospital or medical facility will mix the powdered pembrolizumab injection with fluids and administer it intravenously (into a vein) during a 30-minute period. For as long as your doctor advises you to undergo treatment, it is typically injected once every three or six weeks.

Serious side effects could occur during or soon after the infusion of pembrolizumab injection. Inform your physician right once if you encounter any of the following symptoms: back pain, itching, rash, hives, fever, chills, shaking, lightheadedness, fainting, shortness of breath, or trouble breathing.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place

Marketer details:

Name: MSD Pharmaceuticals Pvt Ltd

Address: Platina, 8th Floor, C.59, G Block, Bandra Kurla Complex, Bandra (East) , Mumbai - 400098,

Country of origin: India

Frequently Asked Questions:

1. What is Keytruda Injection?
Keytruda (Pembrolizumab) is an immunotherapy agent (anti-PD-1 monoclonal antibody) that may be prescribed for certain types of cancer. It works by potentially helping the body's own immune system recognise and respond to cancer cells, though outcomes can vary significantly between patients.

2. What cancers may Keytruda be approved for?
Keytruda has received regulatory approval for use in several oncological indications, which may include:
•         Melanoma
•         Non-small cell lung cancer (NSCLC)
•         Head and neck squamous cell carcinoma
•         Colorectal cancer (MSI-H/dMMR)
•         Urothelial (bladder) cancer
•         Cervical cancer
•         Gastric/gastro-oesophageal junction cancer
•         Triple-negative breast cancer
•         Certain solid tumours with specific biomarker profiles
Approved indications may vary by country and are subject to change. Consult your oncologist for current eligibility.

3. How is Keytruda believed to work?
Cancer cells may evade immune detection by activating the PD-1 checkpoint pathway. Keytruda is designed to block the PD-1 receptor on T cells, which may allow the immune system to recognise and mount a response against cancer cells. However, not all patients respond to this mechanism.

4. How is Keytruda administered?
Keytruda is given as an intravenous (IV) infusion over 30 minutes in a hospital or infusion centre. The typical dose is 200mg every 3 weeks or 400mg every 6 weeks, though schedules may vary depending on the cancer type and the specific clinical protocol.

5. What are the possible side effects of Keytruda?
Some patients may experience:
•         Fatigue
•         Skin rash or itching
•         Diarrhoea
•         Nausea
•         Decreased appetite
•         Shortness of breath
Side effects vary considerably between individuals and may range from mild to severe.

6. What are immune-related adverse events (irAEs)?
Because Keytruda activates the immune system, it may occasionally cause inflammatory reactions in healthy tissues, referred to as immune-related adverse events. These may affect organs such as:
•         Lungs (pneumonitis)
•         Bowel (colitis)
•         Liver (hepatitis)
•         Endocrine glands (thyroid, adrenal, or pituitary disorders)
•         Kidneys (nephritis)
These reactions can occasionally be serious and require prompt evaluation and management by your oncologist.

7. How is Keytruda different from chemotherapy?
Keytruda is an immunotherapy agent, not a cytotoxic chemotherapy. Rather than directly targeting cancer cells, it may help the immune system identify and respond to them. As a result, its side effect profile differs from traditional chemotherapy, though serious adverse effects can still occur.

8. Is Keytruda effective for all patients?
Clinical responses to Keytruda vary considerably. Some evidence suggests that patients with higher PD-L1 expression or high tumour mutational burden (TMB) may be more likely to respond. Biomarker testing is often performed before initiating treatment to help assess the likelihood of benefit in an individual patient.

9. How long may treatment with Keytruda continue?
The duration of Keytruda treatment depends on cancer type, individual response, and tolerability. In some settings, treatment may be continued up to 2 years or until disease progression or unacceptable side effects occur. Your oncologist will guide the treatment duration.

10. Is Keytruda available in India?
Keytruda is available in India for certain approved oncology indications. It is a high-cost treatment, and access may depend on insurance coverage or patient assistance programmes. Consult your oncologist for guidance on availability, eligibility, and cost support options.

11. Is Keytruda a prescription-only medicine?
Yes. Keytruda is a prescription-only oncology medicine administered exclusively under the supervision of a qualified oncologist in an appropriate clinical setting.

Medical Disclaimer:
Keytruda Injection is a prescription-only medicine and must be used strictly under the supervision and guidance of a qualified healthcare professional. Do not self-medicate, alter the dosage, or discontinue use without consulting your doctor. The information provided here is for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Individual results, benefits, and risks may vary. Always consult your physician before starting, changing, or stopping any medication.